The global clinical trial imaging services market is on a robust growth trajectory, presenting a significant opportunity for pharmaceutical companies to enhance their R&D and accelerate drug development. Driven by continuous technological advancements in imaging modalities, the market is projected to expand from USD 1.31 billion in 2023 to USD 2.10 billion by 2033, a notable Compound Annual Growth Rate (CAGR) of 5.41%. As imaging becomes increasingly vital for diagnostics and monitoring in clinical trials, from high-resolution MRI and CT to PET and ultrasound, pharmaceutical companies are poised to leverage this market's potential.
Download the full report now to discover market trends, opportunities, and strategies for success.
https://evolvebi.com/report/clinical-trial-imaging-services-market-analysis/
Problems and the Tariff Headwind
Despite the promising growth, the market is not without its challenges. One of the primary problems faced by pharmaceutical companies is the complex management and integration of the vast volumes of imaging data generated during trials. If not handled properly, this can compromise data quality, reliability, and the overall integrity of the study.
An additional, and increasingly relevant, headwind is the implication of US tariffs. Proposed tariffs, potentially reaching up to 54% on select imports, are causing significant operational strain. They impact the cost and supply chain of critical imported goods, including lab supplies, diagnostic tools, and advanced imaging equipment like CT and MRI scanners. While there is a prototype exemption for clinical trial lots, the rising cost of general supplies and equipment can still increase overall trial expenses, making the US a less attractive location for clinical research, particularly for smaller biotech firms.
Download the full report now to discover market trends, opportunities, and strategies for success.
https://evolvebi.com/report/clinical-trial-imaging-services-market-analysis/
A Path Forward: Proposed Solutions
To overcome these challenges, pharmaceutical companies can adopt a multi-faceted approach. First, leveraging hybrid imaging technologies, such as PET/CT and PET/MRI, offers a powerful solution to the data problem. These technologies provide more comprehensive and detailed insights, streamlining the data analysis process and enhancing the quality of results.
Furthermore, companies can mitigate the impact of tariffs by implementing strategic solutions. One such solution is to explore onshoring manufacturing and supply chains for key trial components and equipment. By developing domestic supply networks, pharmaceutical companies can reduce their exposure to tariff-related costs and disruptions. Additionally, it is crucial to fully understand and utilize the Harmonized Tariff Schedule Code 9817.85, which offers a prototype exemption for importing clinical trial materials duty-free. This can help insulate specific trial costs from tariff impacts.
Download the full report now to discover market trends, opportunities, and strategies for success.
https://evolvebi.com/report/clinical-trial-imaging-services-market-analysis/
To understand further and explore opportunities in the Clinical Trial Imaging Services Market or any related industry, please share your queries/concern at [email protected].
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: [email protected]
Website: https://evolvebi.com/
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing
innovative solutions to challenging pain points of a business. Our market research reports include data
useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere
data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate
data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-
time data including, quarter performance, annual performance, and recent developments from
fortune's global 2000 companies.
This release was published on openPR.
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
Delete press release Edit press release News-ID: 4377835 • Views: 5
